dinoprost and Psoriasis

Topics: 6-Ketoprostaglandin F1 alpha; Blood Pressure; Cyclosporins; Dinoprost; Dopamine; Glomerular Filtration Rate; Humans; Kidney Transplantation; Prostaglandins; Prostaglandins F; Psoriasis; Regional Blood Flow; Thromboxane B2

Twenty-four hour excretion of main urinary metabolite of prostaglandin F1 alpha and F2 alpha (PGF-MUM) in 18 patients with stable psoriasis (9 males and 9 females) and 18 almost age-matched healthy subjects (9 males and 9 females) was examined. The mean excretion level of PGF-MUM in male psoriatic patients (15.2 +/- 4.0 micrograms/day) was significantly lower than that in male healthy subjects (22.8 +/- 3.3 micrograms/day) (p less than 0.01). A similar tendency was observed between female psoriatic patients (10.6 +/- 3.0 micrograms/day) and female healthy subjects (13.3 +/- 2.4 micrograms/day) although the difference in the excretion level was not so remarkable (p = 0.05) compared with male subjects. These results suggest an altered endogenous prostaglandin synthesis in psoriatic patients.

Topics: Adolescent; Adult; Child; Dinoprost; Fatty Acids; Female; Humans; Male; Middle Aged; Prostaglandins F; Prostanoic Acids; Psoriasis; Radioimmunoassay

Topics: 6-Ketoprostaglandin F1 alpha; Dinoprost; Dinoprostone; Humans; Hypersensitivity, Delayed; Prostaglandin D2; Prostaglandins; Prostaglandins D; Prostaglandins E; Prostaglandins F; Psoriasis; Scleroderma, Systemic; Skin; Skin Diseases; Vitiligo